Related references
Note: Only part of the references are listed.6. Glycemic Targets: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM) in patients in the ACCORD trial
Malik Elharram et al.
DIABETES OBESITY & METABOLISM (2021)
Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation
Hiddo J. L. Heerspink et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
Job A. J. Verdonschot et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort
Sang-Ho Jo et al.
DIABETES CARE (2021)
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid
Mario Luca Morieri et al.
DIABETES (2020)
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Joshua D. Wallach et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Distinct Pathological Pathways in Patients With Heart Failure and Diabetes
Jasper Tromp et al.
JACC-HEART FAILURE (2020)
Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors
Milton Packer
CIRCULATION-HEART FAILURE (2020)
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
Li Shen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial
Kinsuk Chauhan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Autophagy and Inflammasome Activation in Dilated Cardiomyopathy
Angela Caragnano et al.
JOURNAL OF CLINICAL MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Franco Cosmi et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
Boris Waldman et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials
Yumo Zhao et al.
DIABETES OBESITY & METABOLISM (2018)
Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
Alessandra Dei Cas et al.
JACC-HEART FAILURE (2015)
Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes
Ichiro Kishimoto et al.
BMJ OPEN DIABETES RESEARCH & CARE (2015)
The PPARα-FGF21 Hormone Axis Contributes to Metabolic Regulation by the Hepatic JNK Signaling Pathway
Santiago Vernia et al.
CELL METABOLISM (2014)
Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice
Bo Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Emily Y. Chew et al.
OPHTHALMOLOGY (2014)
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation
Walter J. Paulus et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study
Ivan Shirinsky et al.
RHEUMATOLOGY INTERNATIONAL (2013)
Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Josyf C. Mychaleckyj et al.
DIABETES CARE (2012)
Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation
Ana Planavila et al.
CARDIOVASCULAR RESEARCH (2011)
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
T. M. E. Davis et al.
DIABETOLOGIA (2011)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Kushwin Rajamani et al.
LANCET (2009)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
A. C. Keech et al.
LANCET (2007)
Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods
John B. Buse
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10-deficient mice
Jimmy W. Lee et al.
GASTROENTEROLOGY (2007)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia
KK Koh et al.
DIABETES CARE (2005)
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
JC Ansquer et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
